AnwaltssucheUnsere KompetenzenDeine KarriereSearch
Standorte
Unsere Kompetenzen
Media Center

Select language:

Standorte
Unsere Kompetenzen
Media Center

Select language:

hamburger menu showcase image
  1. Dohnke Philipp
Hamburg
Dr. Philipp Dohnke
Partner
philipp.dohnke@freshfields.com
Hamburg: +49 40 36 90 60
hero-banner-image
About

Philipp is a member of our intellectual property and information technology team.

Since joining the firm, he has worked across many industries with a particular focus on life science and technologies. Philipp has broad expertise in complex, high-profile transactions, including large carve-out and asset deal projects. In addition, Philipp is experienced in drafting and negotiating complex commercial contracts.

He speaks German and English.

Capabilities
Intellectual property
Mergers and acquisitions
Automotive
Industrials
Life sciences
Connect
Email
VCARD
Download
Additional Information

  • Merck on the sale of its Surface Solutions Business to Global New Material International Holdings Ltd.
  • Barclays on the sale of its German consumer finance business to Austria-based BAWAG Group
  • Näder Holding GmbH & Co. KG on the repurchase of 20% of the shares in Ottobock SE & Co. KGaA from the Swedish private equity firm EQT and a new refinancing of Näder Holding
  • Airbus on its acquisition of INFODAS
  • Deutz on the acquisition of a diesel engine business from Rolls-Royce Power Systems
  • Continental on the sale of its manufacturing site in Kaluga, Russia (as part of Continental's announced controlled exit from the Russian market)
  • Schenck Process Group on the $730M Sale to Hillenbrand of its Food and Performance Materials Business
  • Cinven on its acquisition of MBCC Group’s Admixtures business from Sika AG
  • Eppendorf SE on the sale of its micro manipulation product portfolio to Calibre Scientific
  • Deutz on the acquisition of IP and license rights as well as a collaboration with Daimler Truck in the field of medium- and heavy-duty engines
  • Grünenthal on a joint venture collaboration with Kyowa Kirin International
  • Affimed on a strategic cooperation with Artiva Biotherapeutics for the joint development of a combination therapy in the field of immuno-oncology
  • Umicore on the creation of a joint venture with PowerCo SE, the Volkswagen AG battery subsidiary, to establish the first large-scale supply chain for sustainable batteries for electric vehicles in Europe
  • Grünenthal on its €500m acquisition of testosterone business ("Nebido") from Bayer
  • Special Olympics World Games Berlin 2023 Organisationskomitee gGmbH on the World Games and the National Games in advance, both taking place in Berlin on contractual and intellectual property related matters
  • International Chemical Investors Group (ICIG) on their sale of CordenPharma (leading global CDMO (contract development & manufacturing organization)) to European private equity firm Astorg
  • Osram on the carve-out and sale of its Digital Systems business in North America to Acuity
  • Thermo Fisher on its €725m acquisition of the viral vector manufacturing business of Novasep (Belgium)
  • AstraZeneca on its $39bn acquisition of Alexion Pharmaceuticals
  • Charterhouse / Serb on the $800m acquisition of the BTG Specialty Pharmaceuticals business from Boston Scientific Corporation
  • Novartis on its $5.2bn acquisition of pharmaceutical product Xiidra from Takeda/Shire
  • Merck on its €3.4bn carve-out und sale of its consumer health business to Procter & Gamble
  • Boehringer Ingelheim on its €18bn business swap with Sanofi (Consumer Healthcare against Animal Health)
  • Boehringer Ingelheim on its sale of rights in the pharmaceutical product Buscopan in Brazil to Hypera
  • AstraZeneca / MedImmune on the acquisition of Definiens AG
  • BioNTech on license deals and other collaborations in the field of mRNA products / individualized medicines (including with Pfizer, Genentech, Sanofi, Eli Lilly, Bayer Animal Health and Genmab)
  • Advent International on the $1.9bn acquisition of Sanofi's generics business (Zentiva) and on the add-on acquisition of Alvogen's CEE business
  • Bridgepoint on the acquisition of Pharmazell (manufacturer of active pharmaceutical ingredients)
  • BC Partners on the €2.6bn acquisition of CeramTec
  • BC Partners on the acquisition of a majority stake in the Greek generics company Pharmathen
  • Charterhouse / Cooper on the acquisition of a consumer health product portfolio from Sanofi
  • Charterhouse / Serb on the acquisition of rights in a pharmaceutical product from a US biotech company
  • CVC on the acquisition of a 50% stake in the pharmaceutical excipient manufacturer DFE Pharma from Fonterra (Joint Venture with FrieslandCampina)
  • Cinven/Hotelbeds on the acquisition of the Global Travel Distribution business from Kuoni
  • Continental on the carve-out of its powertrain business ("Vitesco Technologies")
  • Deutsche Bank on the carve-out and listing of its Asset Management business ("DWS")
  • H.I.G. on the carve-out and acquisition of the European polyutherane "system house" business from Covestro
  • Hellman & Friedman on its €2.9bn acquisition of the internet platforms AutoScout24, FinanceScout24 und Finanzcheck

Dr. Philipp Dohnke
Partner
philipp.dohnke@freshfields.com
T +49 40 36 90 60
hamburg Office

Hohe Bleichen 7

20354 hamburg
Download vCard
FINDEN SIE UNS IN
All locations
NAVIGIEREN ZU
About usYour careerOur thinkingOur capabilitiesNews
CONNECT
Find a lawyerAlumniContact us
NEED HELP
Fraud and scamsComplaintsTerms and conditions
LEGAL
AccessibilityCookiesLegal noticesTransparancy in supply chains statementResponsible procurementPrivacy

© 2025 Freshfields. Attorney Advertising: prior results do not guarantee a similar outcome

Select language: